home
01

HLB Healthcare

Founded in 2000, HLB Healthcare is a new drug development company that is developing innovative new drugs in the fields of eye diseases and brain tumors, and is increasing the possibility of developing the "Best-in-class" new drugs through several clinical trials in the United States.

Business Field

Dry Eye Syndrome (DES) treatment

RGN-259 is an anti-inflammatory peptide that is activated in several stages of wound healing and tissue recovery as a medicinal ingredient in Thymosin beta 4. It is a multifunctional substance suitable for dry eye, a multi-personal disease such as tear deficiency or tear membrane disorder caused by excessive tear evaporation and is being developed by a U.S.-based joint venture (ReGen Tree, LLC).

R&D
Graphene Oxide
Carbon Nanotube
Silver Nanoparticle
Photocatalytic Nanoparticle
Gold Nanoparticle
Magnetic Beads

Product

Specimen Collection Swab
Specimen transport medium
Alcohol Swab
Alcohol Swab Blue
eol swab
Product
HQ
address

(30068) 10-5, Myeonghaksandanseo-ro, Yeondong-myeon, Sejong

Tel

+82-44-862-9134

Fax

+82-44-862-9135

HLB
GROUP
LIST
02

Elevar Therapeutics

Since its establishment in 2005, Elevar Therapeutics has developed new drugs for various types of cancer based on its long experience in the development of new anti-cancer drugs and has leapt forward as an anti-cancer drug company through the introduction of new drugs in the research or early clinical stages.

Business Area

Rivoceranib

Rivoceranib is a selective potent inhibitor of vascular endothelial growth factor receptor-2 (known as VEGFR2) which mediates the primary pathway for tumor- mediated angiogenesis. Rivoceranib is a low-molecular inhibitor that is highly regarded as the best-in- class drug due to its high VEGRF-2 selectivity and fewer side effects.

Ongoing Project

- Development of Paclitaxel Micellar, a Cremophor-free formulation of paclitaxel, is underway for the ovarian cancer treatment.
- Increased convenience without prior treatment by applying patent-applied Micelle coating.
- An optimal mixture of Paclitaxel based on the form of additives developed to reduce side effects.

* It received a marketing authorization by the European Medicines Agency (EMA) under the name of medical product Apealea® (paclitaxel micellar) in 2018, and is currently being commercialized in Europe and in the Middle East and North Africa (MENA) region.

Company information
HQ
address

2825 E Cottonwood Pkwy Suite 180,Salt Lake City, UT 84121 U.S.A.

Tel

+1-801-303-7440


Fax

+1-801-303-7455

SFO Office
address

400 Oyster Point Blvd, Suite 214, South San Francisco, CA 94080 U.S.A.

Home

www.elevartherapeutics.com

E-mail

info@elevartherapeutics.com

03

Immunomic
Therapeutics

미국 메릴랜드에 위치한 면역 세포 및 백신 치료제 개발업체로 2006년에 William Hearl 박사에 의해 설립되었습니다. 보유한"UNITE" 플랫폼은 세포치료제 및 DNA/RNA백신과 결합하여 다양한 질병 치료제로 이용될 수 있습니다. 현재 이뮤노믹테라퓨틱스는 “UNITE” 기술을 기반으로 항암, 알레르기 치료제, COVID19 백신 등 다양한 면역 백신 치료제를 개발중입니다.

사업영역

UNITE (차세대 면역치료 플랫폼 기술)

"Universal Intracellular Targeted Expression"의 약자로 특정 항원을 리소좀에 타겟팅하여 항원제시 능력을 높였기 때문에, 세포 독성 T세포 뿐 아니라 기억 T세포, B세포 등 면역 반응을 전방위적으로 활성화시킬 수 있는 강력한 차세대 면역치료 플랫폼 기술입니다. 암과 알레르기 등에 적용 가능하고 확장성이 높습니다.

교모세포종 치료제 등 13개 파이프라인 보유

현재 이뮤노믹테라퓨틱스는 항암, 감염질병, 알레르기 치료제 영역에서 13개의 파이프라인을 보유하고 있습니다. 이중 2상 마무리 단계에 있는 ITI-1000은 교모세포종(GBM) 치료제로, 임상 결과에서 기존 화학치료제보다 5년 생존율은 7배, 전체 생존기간(mOS)는 30개월 이상 높아 뚜렷한 치료제가 없는 교모세포종 시장에서 신규 치료제로서의 승인 가능성을 높이고 있습니다.

기업정보
본사 & 연구소
address

15010 Broschart Road Suite 250 Rockville, MD 20850

Tel

+1-301-968-3501

Home

www.immunomix.com

E-mail

info@immunomix.com

04

Verismo
Therapeutics

Verismo Therapeutics was established in 2020 as a Penn spin-out by the team behind Kymriah, the world's first approved CAR T-cell therapy. Its KIR-CAR platform, the first multichain CAR T-cell construct, has shown superior efficacies in solid tumor models.

Business area

SynKIR™

CAR-T therapy is a cell therapy that utilizes re-engineered patients' T-cells to target and eradicate cancer. The traditional CAR-T therapies based on the artificial single-chain construct have shown their limitations for T cell persistency, indication expansion, and safety. Verismo's multichain KIR-CAR construct, whose structure resembles natural NK-like receptors in humans, is expected to show superior efficacy and safety on solid tumors through the company’s first-in-human clinical trials scheduled to be initiated in 2023.

Various anticancer pipelines

Currently, based on the KIR-CAR platform technology, Verismo is expanding into various pipelines such as mesothelioma, ovarian cancer, pancreatic cancer, GBM, and blood cancers that are relapsed or refractory to traditional CAR T therapies.

Company information
HQ&LAB
address

3675 Market Street, Suite 200 Philadelphia, PA 19104

Tel

+1-215 989-4225

Home

www.verismotherapeutics.com

E-mail

pavel.aprelev@verismotherapeutics.com

05

HLB Life Science
Co., Ltd.

HLB Life Science leaps forward as a global pharmaceutical company based on the discovery of first-in-class / best-in-class innovative new drugs and a differentiated new drug development network based on unmet need analysis.

Business Area

Domestic Research of Rivoceranib

The bio business division of HLBLS is currently developing ‘Best-in-Class’ targeted-anticancer drug Rivoceranib (Apatinib) for marketing approval in Korea. HLBLS plans to maximize the versatility of Rivoceranib by expanding research in various cancer areas (stomach cancer, liver cancer, colon cancer etc.), non-cancer areas (age-related macular degeneration and dry eye disease) and animal cancers.

Seclidemstat: biomarker based solid tumor drug development

Seclidemstat normalizes tumor-related gene expressions that suppress proliferation and metastasis of cancer cells. It regulates lysine-specific histone demethylase 1A(LSD-1) that is over-activated in various tumor cells. It is a first-in-class epigenetic anticancer drug with a new promising MOA.

Company information
HQ
Address

8F, 51-9, Dongtancheomdansaneop 1-ro, Hwaseong-si, Gyeonggi-do, Republic of Korea

Tel

+82-2-2627-6748

Fax

+82-2-2627-6702

Seoul Office
Address

(06193) 420, Teheran-ro, Mayple Tower 15f, Gangnam-gu, Seoul, Republic of Korea

Tel

+82-2-2627-6700

Fax

+82-2-2627-6703

Home

www.hlb-ls.com

E-mail

hlbls@hlb-ls.com

06

HLB Pharma

HLB pharma is a bio healthcare company that is not only paving the way for synthetic peptides, but also growing into a comprehensive biopharmaceutical company with a growing dietary supplement product portfolio. Through its acquisition of the Hyangnam Plant, HLB Pharma has expanded its production capacity, thus taking a leap forward in becoming a global company with a central role within the HLB Bio Eco System.

Business Area

ETC drugs

125 drugs including Roche Duo Tab, Radova Tab, Glitia soft cap, and Ctpezil Tab

OTC drugs

40 drugs including Pramax Cream/Suppositories

CMO

190 drugs including L-Carnitine, Aceclofenac

Health Functional Food

Preparing to launch four products

R&D

CTT-004 (C-Trelin OD Tablet)

Spinocerebellar degeneration is a rare disease in which the cells making up the cerebellum die due to unknown mechanisms. Ataxia is the main symptom caused by spinocerebellar degeneration. As there has been no therapeutic agent with efficacy and safety proven through large-scale clinical trials, HLB Pharma is currently carrying out clinical trial that aims to prove efficacy and safety at major domestic university hospitals, using the taltirelin hydrate.

SMEB® Technology

SMEB (Smart continuous Manufacturing system for Encapsulated Biodrug) technology is the continuous manufacturing technology for long-acting injectable formulations, which have an automatic systems for production and quality control. Currently, HLB Pharmaceutical is conducting research and development of anti-coagulants, dementia treatments, and Parkinson's treatments as well as peptide drugs, and is promoting open innovation with domestic and foreign companies.

Company Information
HQ
address

9F, MK Tower, 67, Jeongui-ro, Songpa-gu, Seoul

Tel

+82 2-411-1500

Fax

+82 2-411-1590

Factory / Lab
address

27, Gyeonggang-ro, Namyangju-si, Gyeonggi-do

Tel

+82 2-577-0001

Fax

+82 31-557-6622

Home

www.hlbpharma.co.kr

E-mail

sail@hlbpharma.co.kr

07

HLB Therapeutics

Founded in 2000, HLB Therapeutics is a new drug development company that is developing innovative new drugs in the fields of eye diseases and brain tumors, and is increasing the possibility of developing the "Best-in-class" new drugs through several clinical trials in the United States.

Business Field

Dry Eye Syndrome (DES) treatment

RGN-259 is an anti-inflammatory peptide that is activated in several stages of wound healing and tissue recovery as a medicinal ingredient in Thymosin beta 4. It is a multifunctional substance suitable for dry eye, a multi-personal disease such as tear deficiency or tear membrane disorder caused by excessive tear evaporation and is being developed by a U.S.-based joint venture (ReGen Tree, LLC).

Neuropathic keratitis (NK) treatment

NK is a rare degenerative corneal disease that causes corneal damage, corneal ulcers, and perforation due to the disorder of trigeminal nerve. It is the area that the mechanism of Thymosin beta 4 is suitable to apply to promote wound healing. It has been designated as an orphan drug by the FDA and is currently undergoing phase 3 clinical trials.

Glioblastoma multimode (GBM) treatment

GBM is a malignant glioma originated from neuroglial cells present in brain tissue. OKN-007 is a treatment that improves hypoxia in the tumor microenvironment and inhibits tumor proliferation by inhibiting angiogenesis. It has been designated as an orphan drug by the FDA.

Company Information
HQ
address

(13554) 22F, 248, Jeongjail-ro, Bundang-gu, Seongnam-si, Gyeonggi-do (Park View Office Tower)

Tel

+82-31-786-7800

Fax

+82-31-786-7801

Home

www.hlbtherapeutics.com

E-mail

hlbtherapeutics@hlbtherapeutics.com

08

Knotus

Knotus provides non-clinical services that pharmaceutical companies need in the early stage of developing medicines. With latest diagnostic equipment and extensive experimental experience in various fields, Knotus has steadily grown as an essential partner of many bio companies by systematically consulting on the needs of customers in the process of developing new substances, establishing itself as a performing institution boasting the highest number of efficacy experiments in Korea.

Business Field

Non-clinical CRO

engages in non-clinical testing of newly developed medicines
focuses on differentiation and efficacy based on veterinary knowledge and imagery interpretation ability

Lab Consulting

Accumulated experience and knowhow in constructing large-scale animal labs
Facility construction, maintenance, and supply of necessary equipment and materials

Animal Bio Business

Ranging from pet supplies distribution to pet medical supplies and consulting

Major Client (pharmaceutical)
Major Client (bio-venture)
기업정보
HQ
address

(22014) 38, Academy-ro 79beon-gil, Yeonsu-gu, Incheon

Tel

+82-32-833-8899

Fax

+82-507-0322-9594

Guri Office
address

(11910) 189, Donggureung-ro, Guri-si, Gyeonggi-do

Tel

+82-31-572-8899

Fax

+82-31-572-6699

Home

www.knotus.co.kr

E-mail

knotus@knotus.co.kr

09

HLB Cell

Founded in 2009, HLB Cell has been focusing on specialized stem cell research, including bio-artificial liver, and biomedical engineering research, with the deepest understanding of "Cell," the fundamental unit of life phenomena, and suggests regenerative medical treatment for incurable diseases. It has differentiated pipelines such as bio-artificial liver, stem cell therapy, and surgical hemostatic agents.

Business Area

Bio Artificial Liver

LifeLiver™ is a cell therapy for prolonging the golden time of patients with acute liver failure waiting for liver transplantation.

Stem Cell Therapy

It is a stem cell therapeutic that can be applied to liver disease (urea dystrophy, nonalcoholic steatohepatitis, etc.) and soft tissue disease by applying mass culture technology to new stem cells derived from human body.

Biodegradable Medical Adhesive
· Sealant

It is a powder-type product that can be used during surgery as well as various external bleedings.

Company information
HQ & Lab
address

8F, 51-9, Dongtancheomdansaneop 1-ro, Hwaseong-si, Gyeonggi-do

Tel

+82-31-372-8578

Fax

+82-31-374-8579

Home

www.hlbcell.co.kr

E-mail

hlbcell@hlbcell.co.kr

10

Hwajin Medical
Co., Ltd.

Since its establishment in 1993, Hwajin Medical has grown into a manufacturer specializing in producing medical devices and currently taking up to 20-25% of the domestic syringe market. The main products are disposable syringes, disposable needles, and filter syringes.

Business Area
Disposable Syringe
Disposable Injection Needle
Membrane Filter Syringe
Certification Status
Delivery Performance
Company information
HQ
address

20, Seongsimwon-gil, Seongnam-myeon, Dongnam-gu, Cheonan-si, Chungcheongnam-do

Tel

+82-41-554-6181

Fax

+82-41-554-7178

Home

www.hwajinmedical.com

E-mail

hwajin@hwajinmedical.com

11

HLB Science

Since its establishment in 2016, HLB science is developing innovative new drugs in the field of treating infectious diseases and Alzheimer’s dementia along with authoritative infection/immune experts.

Business Field

DD-S052(Sepsis treatment)

An innovative new drug candidate with the elimination of bacteria as well as the elimination of endotoxins. So far, it has been proven that it could control the secondary immune response by endotoxins released in antibiotic treatment as well as gram-negative bacteria and is under development as a cure for super bacteria that are causing social problems.

DD-A279(Alzheimer’s dementia treatment)

Through the control of endotoxins and inflammatory cytokines that cause nerve cell death and cognitive dysfunction, it is being developed as a new mechanism for Alzheimer's dementia, which has no fundamental treatment and is becoming a social problem worldwide.

Leading company in developing sepsis (super bacteria antibiotic)/Alzheimer’s dementia treatment Development of septicemia treatment

Company information
HQ
address

(04782) 6F, 66, Achasan-ro, Seongdong-gu, Seoul

Tel

+82-2-6925-0379

Fax

+82-70-8280-0378

R&D Center
address

(18469) 8F, 51-9, Dongtancheomdansaneop1-ro, Hwaseong-si, Gyeonggi-do

Fax

+82-70-5165-0011

Home

www.hlbscience.com

E-mail

hlbscience@hlbscience.com

12

Shinhwa Advance
Co., Ltd.

Since its establishment in 1991, Shinhwa Advance is a professional drug distribution company with leading domestic and foreign pharmaceutical companies such as Yuhan Corporation and Pfizer as clients. It is continuously expanding its distribution portfolio and pursuing business collaborations with large hospitals such as university and general hospitals.

Business Area

Wholesale of medicine.

Distribution of general and specialized drugs to drug wholesalers and large hospitals through direct transactions with pharmaceutical companies.

In-person pharmacy sales

Distribution of general and specialized drugs to pharmacies near hospitals through direct transactions with pharmaceutical companies.

Medical supplies and consumables

Provision of logistics and purchasing agency services for medical and surgical supplies, consumables, etc. required by hospitals.

Delivery Performance
Overseas Major Client
Company information
HQ
Address

150-858 191, Daebangcheon-ro, Yeongdeungpo-gu, Seoul (2nd floor of Shinhwa Building)

Tel

+82-2-834-7971

Fax

+82-2-834-7938

E-mail

shparm7@hanmail.net